No connection

Search Results

QUCY vs SNYR

QUCY
Mainz Biomed N.V.
BEARISH
Price
$0.49
Market Cap
$6.1M
Sector
Healthcare
AI Confidence
95%
SNYR
Synergy CHC Corp.
BEARISH
Price
$0.52
Market Cap
$5.9M
Sector
Healthcare
AI Confidence
95%

Valuation

P/E Ratio
QUCY
--
SNYR
--
Forward P/E
QUCY
--
SNYR
1.04
P/B Ratio
QUCY
7.38
SNYR
-0.26
P/S Ratio
QUCY
11.35
SNYR
--
EV/EBITDA
QUCY
-0.6
SNYR
-3.62

Profitability

Gross Margin
QUCY
72.58%
SNYR
66.83%
Operating Margin
QUCY
-2159.86%
SNYR
-219.45%
Profit Margin
QUCY
0.0%
SNYR
-40.62%
ROE
QUCY
-488.32%
SNYR
--
ROA
QUCY
-89.61%
SNYR
-39.89%

Growth

Revenue Growth
QUCY
-32.9%
SNYR
-41.0%
Earnings Growth
QUCY
--
SNYR
--

Financial Health

Debt/Equity
QUCY
4.01
SNYR
--
Current Ratio
QUCY
0.5
SNYR
1.22
Quick Ratio
QUCY
0.27
SNYR
0.71

Dividends

Dividend Yield
QUCY
--
SNYR
--
Payout Ratio
QUCY
0.0%
SNYR
0.0%

AI Verdict

QUCY BEARISH

QUCY exhibits severe financial distress, anchored by a weak Piotroski F-Score of 3/9 and a critical liquidity crisis evidenced by a Current Ratio of 0.50. The company is suffering from catastrophic operational inefficiency with an operating margin of -2159.86% and a massive ROE of -488.32%. Despite beating negative earnings estimates, the fundamental trend is one of collapse, with revenue declining by 32.90% YoY and a 5-year price depreciation of 98.2%. The combination of high leverage (Debt/Equity 4.01) and shrinking revenues suggests a high risk of insolvency.

Strengths
Strong Gross Margin (72.58%) indicating product value
Recent trend of beating EPS estimates (3/4 quarters)
Positive Q/Q EPS growth (+38.5%) although still deeply negative
Risks
Severe liquidity risk with a Quick Ratio of 0.27
Extreme operational losses (Operating Margin -2159.86%)
Significant revenue contraction (-32.90% YoY)
SNYR BEARISH

SNYR exhibits severe financial distress, highlighted by a critical Piotroski F-Score of 1/9 and a negative Price-to-Book ratio of -0.26, indicating negative shareholders' equity. The company is experiencing a collapse in top-line growth with revenue declining 41% YoY and a catastrophic Q/Q EPS growth of -3600%. Despite a 'strong_buy' analyst consensus and a target price of $6.25, the fundamental data shows a company in a death spiral with a 78.9% one-year price decline and zero earnings beats in the last four quarters.

Strengths
Strong Gross Margin of 66.83%
Current Ratio of 1.22 suggests short-term liquidity is currently maintained
Positive analyst sentiment (though disconnected from fundamentals)
Risks
Negative equity (P/B -0.26) indicating potential insolvency
Severe revenue contraction (-41% YoY)
Extreme earnings volatility and massive misses (Average surprise -1871.45%)

Compare Another Pair

QUCY vs SNYR: Head-to-Head Comparison

This page compares Mainz Biomed N.V. (QUCY) and Synergy CHC Corp. (SNYR) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile